ISIN | LU0432979614 |
---|---|
Valor Number | 10261626 |
Bloomberg Global ID | |
Fund Name | JPM Global Healthcare Fund A acc USD |
Fund Provider |
J.P. Morgan Bank Luxembourg S.A.
6, route de Trèves L-2633, Senningerberg Grand Duchy of Luxembourg |
Fund Provider | J.P. Morgan Bank Luxembourg S.A. |
Representative in Switzerland |
JPMorgan Asset Management (Switzerland) LLC Genève Phone: +41 22 744 11 11 |
Distributor(s) |
JP Morgan Asset Management (Europe) Sàrl Senningerberg Phone: +352 34 10 1 |
Asset Class | Equities |
EFC Category | Equity Health Care |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally. |
Peculiarities |
Current Price * | 458.59 USD | 17.04.2025 |
---|---|---|
Previous Price * | 459.75 USD | 16.04.2025 |
52 Week High * | 557.48 USD | 03.09.2024 |
52 Week Low * | 437.61 USD | 09.04.2025 |
NAV * | 458.59 USD | 17.04.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 3,903,793,006 | |
Unit/Share Assets *** | 1,000,111,109 | |
Trading Information SIX |
YTD Performance | -2.02% |
31.12.2024 - 17.04.2025
31.12.2024 17.04.2025 |
---|---|---|
YTD Performance (in CHF) | -12.23% |
31.12.2024 - 17.04.2025
31.12.2024 17.04.2025 |
1 month | -7.14% |
17.03.2025 - 17.04.2025
17.03.2025 17.04.2025 |
3 months | -4.27% |
17.01.2025 - 17.04.2025
17.01.2025 17.04.2025 |
6 months | -13.30% |
17.10.2024 - 17.04.2025
17.10.2024 17.04.2025 |
1 year | -6.40% |
17.04.2024 - 17.04.2025
17.04.2024 17.04.2025 |
2 years | -4.94% |
17.04.2023 - 17.04.2025
17.04.2023 17.04.2025 |
3 years | -7.28% |
19.04.2022 - 17.04.2025
19.04.2022 17.04.2025 |
5 years | +22.50% |
17.04.2020 - 17.04.2025
17.04.2020 17.04.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Eli Lilly and Co | 9.06% | |
---|---|---|
UnitedHealth Group Inc | 8.42% | |
Johnson & Johnson | 6.71% | |
AbbVie Inc | 6.26% | |
AstraZeneca PLC | 4.94% | |
Boston Scientific Corp | 3.82% | |
Bristol-Myers Squibb Co | 3.78% | |
Sanofi SA | 3.73% | |
Medtronic PLC | 3.53% | |
Stryker Corp | 3.04% | |
Last data update | 31.03.2025 |
TER *** | 1.69% |
---|---|
TER date *** | 31.12.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.50% |
Ongoing Charges *** | 1.69% |
SRRI ***
|
|
SRRI date *** | 31.03.2025 |